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COMBINATION THERMOCHEMOTHERAPY FOR THE TREATMENT OF NONMUSCLE INVASIVE BLADDER CANCER. Ramy Goueli, Darryl Martin, Marcia
Wheeler and Robert Weiss. Department of Urology, Yale University School of Medicine,
New Haven, CT.
Bladder cancer is the fourth most commonly diagnosed malignancy and is the eighth
leading cause of cancer death among men in the United States of America. Furthermore,
it is the seventh and seventeenth most common cancer among males and females,
respectively with increasing incidence among Caucasian compared with other ethnicities.
Thus it is of utmost importance to develop strategies to improve our ability to early
diagnose as well improve treatments by developing new drugs or develop novel
treatments. We hypothesized that improving drug potency by enhancing their uptake into
tumors will improve their clinical efficacy and enhance tumor killing. We investigated
the efficacy of hypothermia in synergizing the effect of various chemical therapeutic
agents using different cell bladder types. The combination of hyperthermia and
chemotherapeutic agents showed promising results. Hyperthermia enhanced the effect of
drugs in reducing the amount of drug required to decrease the number of cells by 50%
(LD50). However, the effect was variable depending on cell type and the drug tested. We
also showed that hyperthermia alone increased the depth of penetration and density at
which nanoparticles could penetrate the bladder. Thus, combination hyperthermia and
chemotherapy holds promise for the treatment of superficial bladder cancer both as an
initial therapy and as a salvage therapy.
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I.

INTRODUCTION

Significance
Bladder cancer is the fourth most commonly diagnosed malignancy and is the
eighth leading cause of cancer death among men in the United States of America.
Furthermore, it is the seventh and seventeenth most common cancer among males and
females, respectively[1] with increasing incidence among Caucasian compared with
other ethnicities [2, 3]. The probability for developing invasive bladder cancer in the
United States is 3.81% and 1.15% for men and women, respectively [3].
Staging of Bladder carcinomas
Staging of bladder cancer from T0 to T4 is dependent on the depth of tumor
penetration and the depth of tumor penetration from T0 to T4 is correlated with clinical
outcome. Stage T0 denotes no evidence of primary tumor. Ta and carcinoma in situ (Tis)
do not invade the lamina propria but rather grow along the urothelial surface [4, 5]. Once
there is invasion to the lamina propria, the tumor is staged as T1, which is further divided
into T1a and T1b lesions; where T1b lesions have a deeper invasion past the lamina
propria and into the muscularis mucosa [6, 7]. Stage T2 lesions denote invasion into the
muscularis propria, and also is subdivided into T2a where there is invasion into the inner
half of the muscle layer, and T2b where there is deeper invasion into the muscle layer.
When the tumor invades beyond the bladder wall, it is staged as either a T3 or T4. A T3
lesion denotes invasion into the perivesical tissue/fat, either microscopically, T3a, or
macroscopically T3b[8]. T4 lesions denote that the tumor invasion extends beyond the
perivesical tissue. These lesions are further stratified as T4a lesions when the tumor
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invades the uterus, vagina, or prostatic stroma, and T4b lesions whe the tumor invades
either the pelvic or abdominal walls [9, 10].
Approximately 90% of bladder cancers are urothelial cell carcinomas (UCC)
while a small percentage

are classified as squamous cell carcinomas (SCC) or

adenocarcinomas [11]. In Egypt, bladder cancer is the most common malignancy among
males, and is mainly attributed to Shistosomal infections leading to SCC, although the
trend is transitioning to UCC with the increased use of anti-parasitic treatments [12]. Of
the urothelial cell carcinomas, about 70-85% are superficial (Ta, T1, carcinoma in situ)
at presentation, and are classified as non-muscle invasive bladder cancer (NMIBC) [13,
14]. For patients that present with muscle invasive bladder cancer (T2-4), outcomes are
poor; and nearly half die within five years of their diagnosis [14, 15].
Risk factors
Smoking is a major risk factor for urothelial cell carcinoma of the bladder and
increases the likelihood of developing the disease by four-fold as compared to individuals
who never smoked. The risk is directly connected to smoking duration, quantity of
cigarettes, and the age of smoking initiation [16-18]. Additional risk factors include
occupational hazards such as carcinogens (aniline dyes, aromatic amines, polyaromatic
amines and arsenic), pelvic radiation, cyclophosphamides, the oral antibiotic drug
pioglitazone, and exposure to Aristolochia fangchi (a Chinese herb) [19].
Diagnosis
The most common initial presentation of bladder cancer is hematuria, either
macro- or microscopic. Gross hematuria (macroscopic) has been shown to carry a 19%
chance of urinary tract malignancy, while microscopic hematuria has a 5% chance of
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urinary tract malignancy [20, 21]. Additional symptoms that are associated with bladder
cancer include irritative voiding symptoms (dysuria, urgency, increased frequency), in
the absence of an infection. Rarely, patients will present with signs of advanced disease
such as, cachexia and abdominal or bone pain.
If bladder cancer is suspected, the patient should undergo a urine sample for
cytology, upper urinary tract imaging, and a diagnostic cystoscopy. Urine cytology has an
overall sensitivity of 30-50%. It is most sensitive (up to 90%) for patients with high grade
tumors and CIS as these tumors often shed malignant cells [22]. Upper urinary tract
imaging can help confirm the presence of upper tract tumors and include intravenous
urography, retrograde pyelography, CT urography, and MRI studies [1]. Despite the use
of urine cytology and imaging, cystoscopy continues to remain the gold standard for
diagnosing bladder cancer, with a sensitivity of 94%, although it has a 60% sensitivity for
diagnosing CIS [23, 24].
Transurethral resection of the bladder tumor (TURBT) is the initial diagnostic
procedure for patients with bladder cancer. TURBT allows for more accurate staging,
decreases or eliminates tumor burden, and helps dictate further treatment options [25]. If
the tumor is found to be muscle invasive (T2 or higher) but organ confined the definitive
treatment is radical cystectomy with a urinary diversion, although it may cure only 50%
of patients [25, 26]. When systemic chemotherapy is indicated, for metastatic disease,
there are several neoadjuvant and adjuvant options which include an MVAC regimen
(Methotrexate, Vinblastine, Adriamycin, and Cisplatin), gemcitabine, or platinum based
drugs. Although these agents have improved survival rates, they are also known to have
severe toxic side effects. [27-29].
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Treatments
A significant portion of NMIBC tumors will recur after treatment and many will
display tumor progression. All patients require long-term follow-up with urine cytology
and cystoscopy. The overall sensitivity of urine cytology is approximately 35% [30, 31]
and cystoscopy is intrusive, uncomfortable to the patients, and costly. In addition,
because of the need for monitoring the patients for an extended period of time, the cost
per case for bladder cancer can be among the highest among all cancer types. Direct
delivery of drugs into the bladder has proven to be an effective method to ensure
maximal delivery of therapeutics to the site of the disease and to minimize systemic side
effects[32]. The effectiveness of the treatment depends on the residence time of the drug
inside the bladder and its binding to and penetration of the bladder wall.
The current therapies for bladder cancer, after TURBT, are intravesicular
instillations of Bacillus Calmette-Guerin (BCG) or Mitomycin C (MMC). BCG is an
attenuated mycobacterium that was originally developed as a vaccine for tuberculosis,
but over the course of the past 20 years has become a standard for the treatment of
NMIBC[33] . Although the mechanism of action of BCG is not fully understood, it is
believed to cause the release of several cytokines (interferon-γ, interleukin-2, tumor
necrosis factor) in the bladder, which ultimately trigger a non-specific immune response
that results in the release of macrophages, T cells, B cells, and natural killer cells [34].
BCG is effective against NMIVC in preventing disease, and is the only drug proven to
decrease disease progression. In addition, it is the only agent approved by the US Food
and Drug Administration for treatment of CIS [35-37]. However, the response to BCG is
unpredictable; approximately 20% of patients discontinue therapy due to side-effects,
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30% of patients do not respond to BCG therapy, and more than 25% of patients have
disease progression despite treatment [38-40].
Mitomycin C (MMC) is an anti-tumor antibiotic that inhibits DNA synthesis
through crosslinking DNA strands [41]. MMC is a relatively large drug, 329g/mol, which
greatly reduces its transurothelial absorption [42]. In terms of overall survival benefit,
MMC has similar results to BCG, although, unlike BCG it has not been shown to
decrease disease progression [43-45]. When MMC and BCG maintenance therapy was
compared in large meta-analyses for the treatment of patients with Ta and T1 UCC, it
was shown that BCG was superior at decreasing tumor recurrence in Ta and T1 UCC
populations compared to MMC [35, 46, 47]. Other classes of chemotherapeutics that
have been tested for the treatment of bladder cancer with some efficacy include
antimetabolites (methotrexate, 5- fluorouracil), microtubule inhibitors (docetaxel,
paclitaxel), and additional anti-tumor antibiotics (epirubicin, doxorubicin) [48-51].
Histone acetyl transferases (HATs) and histone deacetylases (HDACs) are known
signaling enzymes that are implicated in several biochemical processes including
transcription and translation and thus are involved in cellular differentiation,
proliferation, and cell death. Inhibitors of HDAC (HDACis) induce transformed cell
cycle arrest, terminal cell differentiation, and cell death through activation of the
apoptotic pathway. HDACis also block angiogenesis [52, 53]. In fact, one HDACI
(vorinostat) has been approved by the FDA for treating patients with cutaneous T-cell
lymphoma, and at least 12 different HDACis have been evaluated in over 100 clinical
trials involving patients with hematologic and solid tumors including lung, breast,
pancreas, renal, and bladder cancers, melanoma, glioblastoma, leukemia, lymphoma, and
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multiple myeloma. These inhibitors are effective in inhibiting the growth of transformed
cells and are relatively less toxic for normal cells [54]. The histone deacetylase inhibitor,
Belinostat (PXD101), represents a promising new anticancer therapy, which presently is
under Phase III clinical trial.
Barriers to Current Therapies
The urothelium is the epithelial layer of the bladder and represents the major
barrier to the permeation of drugs into the bladder wall. Thus, altering the permeability of
the urothelium by minimizing trans-epithelial resistance may enhance drug delivery and
efficacy[32]. The two main approaches to increase drug permeability of the urothelium
include physical methods and chemical permeation enhancers. Due to the limited
permeability of the bladder wall and the undesired side-effects of chemical enhancers
such as dimethyl sulfoxide (DMSO) or protamine sulfate (PS), it is of interest to devote
efforts to either designing carriers to deliver drugs into the bladder wall or to modulate
therapy by enhancing drug attachment to the bladder wall [55, 56]. Examples of carriers
under current development include liposomes, cell-penetrating peptides, thermosensitive
hydrogels and PLGA nanoparticles. These have shown some positive results in the
treatment of NMIBC, but more research is needed before they become clinically useful
therapeutic strategies [55, 57-61]. It has been demonstrated that modulating therapy
through new techniques such as electromotive drug administration, which modulates the
intravesicular electric field to enhance drug penetration, is more effective than passive
diffusion in delivering drugs deeper into the bladder [62-64]. An additional technique that
recently has been re-visited is the addition of hyperthermia to current intravesicular drug
instillations.
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Hyperthermia
The addition of hyperthermia to drug therapy has been shown to improve patient
outcomes in several cancers, including melanoma, head and neck cancer, breast cancer,
pancreatic cancer, peritoneal cancers, ovarian, cervical and rectal cancers [65-70].
Hyperthermia has a multifactorial effect on tumor growth and whole body physiology
including, independent, cytotoxic effects, vascular effects, immune effects, and
thermosensitization effects[71]. The rationale of introducing hyperthermia is to make use
of the difference in heat tolerance between normal and neoplastic cells; hyperthermia
selectively kills the cancerous cells [72].
Therapeutic hyperthermia has a biphasic direct cytotoxic effect on exposed cells.
The first phase exists between 41°-43°C, showing a reversible growth arrest on the
exposed cells, with a reduction in RNA and DNA synthesis. At these temperatures, there
is a cell cycle arrest at the DNA synthesis phase of the cell cycle (S) as well as at the
mitosis(M) phases, which have been shown to have the greatest degree of nuclear
fragility[73]. The second phase of direct cytotoxicity is at temperatures above 43°C
which cause an irreversible growth arrest , with protein denaturation, impaired DNA
repair, and ultimately, apoptosis[74, 75].
The effects of hyperthermia on the vasculature have been well studied. Heating
the tissue to between 38°-43°C selectively targets tumor-specific vasodilation leading to
increased drug delivery, direct corpuscular injury, and intravascular thrombosis related to
local acidosis. Heating the tissue beyond 43°C causes endothelial cell swelling,
microthrombosis, and increased vascular permeability which ultimately decreases tumor
blood flow and drug delivery[76-79].
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The increase in temperature, mimics fever-like conditions and causes several
effects on the immune system. When the tissue is heated to 38°-43°C there is an
upregulation of heat shock proteins which act as danger signals to the body to activate
dendritic cells and other antigen-producing cells [80, 81]. Subsequently, the dendritic
cells can recruit CD8+ cytotoxic cells which then induce an anti-tumor immune response.
In addition, hyperthermia improves lymphocyte trafficking by increasing the expression
of Inter-Cellular Adhesion Molecule 1(ICAM-1), Interleukin-6 and Interleukin-10, which
helps increase the density of tumor-recognizing T cells in the area[82, 83]. Lastly,
hyperthermia leads to a chemokine release from the tumor cells which has an effect on
the innate immune system by activating natural killer cells to target these tumor cells[8486]. At higher than fever-range temperatures, greater than 43°C, there is a down
regulation of heat shock proteins and local immunosuppression[87].
When therapeutic hyperthermia (43°C) was tested on normal bladder cancer cells
and five different UCC cell lines, it was shown that the effects on bladder cells was
highly variable and limited [88]. Further studies investigated the effect of supraphysiological hyperthermia (40°-70°C) on three UCC cell lines and showed that the
higher the cytologic grade, the lower the tolerance to heat; however, these studies lack
clinical application as they used supra-therapeutic dosages of heat [89]. The synergistic
effect of combining chemotherapy and hyperthermia was studied in vitro. In addition, van
der Heijden and colleagues investigated the effect of combining hyperthermia with
varying concentrations of mitomycin C, epirubicin, gemcitabine, and a bioreductive
alkylating indoloquinone (E09) on four bladder cancer cell lines. In these studies, they
clearly demonstrated a variable synergistic relationship between hyperthermia and drug
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administration for all drugs tested across all cell lines, with the greatest synergism shown
with E09 [90, 91]. A small singular animal study was performed on sheep with an hour
treatment of hyperthermia (41°-43°C) and mitomycin C, and showed that this
combination was safe, as there was no irreversible damage to adjacent organs nor to the
bladder itself [92]. An additional preclinical study was performed to investigate the
effect of temperature on urine viscosity. It was discovered that the viscosity of human
urine was dependent on temperature, while being independent of specific gravity, age,
gender, glycosuria, ketonuria and hematuria [93].
Several clinical studies have been performed to investigate the effects of
combined hyperthermia with mitomycin C therapy [87, 94-107]. Hyperthermia was
proven to increase systemic absorption of Mitomycin C, to a level up to 20ng/mL
(myelosuppression occurs at 400 ng/mL), indicating that the addition of heat can increase
the depth at which MMC penetrates the bladder [105]. A systematic review of the
published literature showed that the combination of MMC and hyperthermia caused a
59% reduction in NMIBC recurrence when compared to MMC treatment alone [87, 97,
98]. Moreover, the effect of hyperthermia and chemotherapy may be longer lasting than
current therapy, with a 3-5 year disease free rate of between 40-50% [103, 104, 108]. In
addition, there has been evidence that the combination can reduce the risk of disease
progression when compared to patients receiving MMC, alone [103]. However, it also
was shown that combination chemotherapy plus hyperthermia increases side effects.
These effects are not life threatening, they do not prevent patients from completing
therapy, and resolve spontaneously after completing therapy [90, 100, 108].
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Model System
It is well recognized that whole animal xenograft and orthotopic models are the
gold standard for testing drug delivery to cancer cells. However, these models are
cumbersome, expensive, time consuming and difficult for quantitative assessment of
tumor size at various time points. Alternative models available include testing drugs on
cells grown in monolayers or 3-D cultures.

However, although superficial bladder

cancer cells grown in monolayer are highly sensitive to cytotoxic agents, they do not
simulate the resistance often seen in multilayered cell populations in vivo[109]. The
benefits of using a system that combines the positive attributes of the whole animal
model and the ease of manipulation of cells in culture, with minimal toxicity to other
tissues or organs has been demonstrated. The organ culture model consisting of a cocultured explanted rat bladder with bladder cancer cells, as simulation of the in vivo
animal model was investigated [110]. The strength of this model is that it allows tumor
cells to interact with transitional epithelium, extracellular matrix, and muscle of bladder
[111].
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II.

HYPOTHESIS AND AIMS
Conflicting reports on the synergistic effect of chemotherapy and hyperthermia

have been published [90, 91]. Those studies reported variable efficacies of the synergistic
effect of hyperthermia with several agents such as MMC, gemcitabine, epirubicin and
E09 in four bladder cancer cell lines. These studies also were limited to three cell lines
(RT112, RT4, T24) of low-grade disease, with only one cell line (253J) representing
high grade invasive disease. In our study, we sought to expand the bladder cancer cell
lines to include both low-grade cell lines (RT4, T24) and high-grade (UM-UC-3,
TCCSUP) cell lines. The UM-UC-3 cell line represents a model of high-grade invasive
disease whereas the TCCSUP cells represent a model of high-grade, invasive disease
with metastatic potential. Additionally, by testing the effects of the combination of MMC
and hyperthermia on cell proliferation, we could compare our study with earlier studies in
order to clarify the numerous inconsistencies in earlier studies that also combined MMC
and hyperthermia.
Thus, the followings are the overall goals of our studies:
1. To characterize the effects of hyperthermia on bladder physiology and test if the
addition of hyperthermia can act synergistically with chemotherapeutic agents.
We aim to test this system using hyperthermia combined with doxorubicin,
vinblastine, methotrexate, cisplatin, and belinostat to determine whether the effect
of combined therapies is bladder cell line specific. Towards this goal, we will use
various biochemical and molecular techniques to monitor the effects of treatments
using tissue culture models. We hypothesize that hyperthermia will increase the
efficacy of all chemotherapeutic agents, and be more effective in the invasive,
higher grade urothelial carcinoma cell lines.
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2. To investigate the effect of hyperthermia on mouse bladder urothelium and detail
the histologic, gross changes since no studies have been published detailing the
effect of hyperthermia, alone, on normal bladder urothelium. We hypothesize that
hyperthermia primarily affects the urothelium by, reversibly, affecting the tight
junctions to allow for deeper penetration of the intravesicular agent. We do not
believe that the hyperthermia will have any effect on the underlying smooth
muscle layer. Conversely, supra-therapeutic temperatures will cause necrosis of
the urothelium with sloughing of tissue. The effect of hyperthermia on penetration
of drug has been investigated previously in vivo, however, the authors used
systemic concentration of MMC as a surrogate marker for penetrance [105].
3. To establish an ex vivo bladder cancer model that has the ability to mimic cancer
growth and invasion. This system may improve the testing of combinations of
hyperthermia and chemotherapy.
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III.

MATERIALS AND METHODS

Cell lines and culture conditions
The human urothelial cell carcinoma cell lines used in this study were RT4, T24,
UM-UC-3 and TCCSUP. The cell lines were purchased from the American Type Culture
Collection (ATCC), all four cell lines originated from primary bladder tumors. These cell
lines varied in levels of differentiation, invasiveness and metastatic potential (Table 1)
[112]. The RT4 cell line was originally isolated from a 63 year old male with transitional
cell papilloma; it behaves in vitro as a low-grade superficial tumor [113, 114]. The T24
cell line was isolated from an 81 year old Caucasian female with low-grade invasive
UCC. It is the most well-differentiated of the invasive UCC cell lines [115-117]. The
RT4 and T24 were cultured in McCoy’s 5A medium (ATCC) supplemented with 10%
fetal bovine serum (FBS, Gibco), penicillin G (100 U/mL), streptomycin (100 µg/mL),
and 1% L-Glutamine. The UM-UC-3 cell line was derived from a male with invasive
transitional cell carcinoma. Unlike T24, it is a high-grade lesion. In addition, it is used in
xenograft models because of its ability to produce tumors in athymic nude mice [118].
The TCCSUP cell line was isolated from a 67 year old female with anaplastic UCC that
had metastasized to the bone. This cell line is the most undifferentiated, invasive cell line
with metastatic potential [119]. The UM-UC-3 and TCCSUP cells were cultured in
Dulbecco’s Eagle’s Minimum Essential Medium (DMEM) (ATCC) supplemented with
10% FBS, penicillin G (100 U/mL), streptomycin (100 µg/mL), and 1% L-glutamine.
All four cell lines were grown in a monolayer on 100 mm2 culture dishes (Corning) at
37°C in a 5% CO2 humidified atmosphere. The cells were grown to 75-80% confluence
and detached using a 0.25% trypsin EDTA mixture (Gibco).
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Thermo-chemotherapy treatment
The thermo-chemotherapy treatments began by seeding all four cell lines (RT4,
T24, UM-UC-3, and TCCSUP) onto 96-well microtiter plates (Falcon) at a concentration
of 1.0 104 cells per well. The plates were placed under normal conditions for a 24 hour
attachment period to allow the cells to attach to the plate. Following the 24 hours, the
medium was changed and the plates were treated with increasing concentrations of
various chemotherapies diluted in cell specific culture media. The chemotherapies tested
were mitomycin C (Fischer Scientific) 0-1000µg/mL, doxorubicin (Sigma) 0-500µg/mL,
vinblastine (MP Biomedical) 0-1000µg/mL, cisplatin (Santa Cruz) 0-2.5mM,
methotrexate (MP Biomedical) (0-500µM) and belinostat (TopoTarget) 0-1mM.
Subsequently, replicate plates were transported to a 5% CO2 humidified incubator at
either 37°C or 42.5°C. Following 60 minutes of treatment the chemotherapies were
aspirated and the cells were washed three times in normothermic (37°C) culture specific
media. The cells were then left for 24 hours in a 5% CO2 humidified incubator at 37°C.
WST-1 (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 3-benzene
Disulfonate) assay
Cell viability was tested using a colorimetric assay, WST-1 solution (Clontech)
which is suitable for an in vitro model. The assay is based on the enzymatic cleavage of
the tetrazolium salt WST-1 to formazan by cellular mitochondrial dehyrogenases present
in viable cells. Twenty-four hours after treatment, the cell media was aspirated and
100uL of pre-mixed WST-1 (final dilution 1:10) was added to each well. Following the
addition of WST-1 the cells were placed in a 5%CO2 humidified incubator at 37°C for
0.5 to 4 hours. The cell viability was determined on a plate reader (Molecular Devices
SpectraMax 250) by measuring the absorbance at 420-480nm. For chemotherapies where
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the LD50 was achieved, three independent experiments were performed; all experiments
were done in quintuplicate. Conversely, for chemotherapies that either showed no activity
or the LD50 were not achieved, two independent experiments were performed, in
quintuplicate, to minimize the possibility for systematic errors.
LD50 and cell viability calculations
To calculate the LD50 of the chemotherapeutic agents, the data were normalized
where untreated cells were considered to have 100% cell survival. Previous literature has
shown that cell killing by hyperthermia alone was minimal [88, 91]. Our own data
mirrored these results (Table 2) thus we could confidently set untreated cells to have
100% cell survival for both temperature conditions. An ANOVA was performed for each
cell line comparing the cell viability data independently at both temperatures for all
dosages tested using GraphPad Prism Software (Graphpad Software, Inc.). If the
ANOVA proved statistical significance for the dosages, then the data were modeled to a
two phase decay equation using GraphPad Prism software (GraphPad Software, Inc.):

A correlation coefficient was generated from the model, R2, and was used as our measure
for “goodness of fit.” Using the generated equations, we were able to approximate the
LD50 and cell viability data. To show that the two conditions showed a significant
difference, statistics were performed using the GraphPad Prism Software.
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Synergism calculations
The equation used to approximate the synergism between chemotherapy and
hyperthermia after 60 minutes of therapy (ST(60)) was derived and adapted from van der
Heijden, Jansen et al. 2004 [90]. The equation is as follows:

The drug concentrations used in the

calculation is the LD50 for each cell type

determined under hyperthermic conditions. For each chemotherapeutic agent and cell
line, synergy was tested using a two-sided unpaired t-test using the Holm-Sidak method
for multiple comparisons with a confidence level of 95% and α=0.05.
Mouse bladder hyperthermic model
All mouse studies were approved by the Institutional Animal Care and Use
Committee of Yale University (New Haven, CT). To test the effects of hyperthermia
alone on the bladder, C57BL/6 Mice (Charles River Laboratories) were euthanized using
20% isoflurate in propylene glycol followed by cervical dislocation when mice no longer
responded to toe pinch, in a method congruent with the recommendation of the Panel on
Euthanasia of the American Veterinary Medical Association. Following euthanasia, the
mice bladders were removed sterilely and transferred to a chemical safety hood, where
the ureters and urethra were removed, and the bladder was cut into four equal pieces.
After washing the explants in sterile PBS, the pieces of tissue were suspended in sterile
PBS and placed into separate eppendorf tubes (GeneMate). The tissue pieces were placed
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in a humidified incubator at 37 ° C, 42.5°C, or 50°C. The tissue was allowed to
equilibrate to the temperature for 15 minutes and then was maintained at that temperature
for either one hour, two hours, or 24 hours. The control was mouse bladder tissue fixed
immediately after its removal. Following treatment the tissue was fixed in 10% neutral
buffered formalin (VWR international) for 24 hours and transported in 70% Ethanol
(Decon). The tissue was sectioned and H&E stained by Yale pathology tissue services
(Developmental Histology Lab). Imaging was performed using a light microscope
(Olympus) and images were taken using the AM Scope camera. Three independent
experiments were performed and independently analyzed by members of the Weiss lab in
the Department of Urology, under single-blinded conditions.
Human urothelium penetration studies
The use of human tissue was approved by the Human Investigation Committee at
Yale University (protocol: 0710003157). To determine the penetration of drug under
hyperthermic conditions human ureter, de-identified tissue was obtained from Yale
urologic surgeons. The ureter was maintained in sterile normal saline and used within
four hours of collection. The tissue was cleaned and washed in sterile normal saline,
following washing the tissue, it was bisected, placed in an autoclaved 96-well dot blot
chamber (Biorad) with the luminal urothelium facing upward. PLGA (poly(lactic-coglycolic acid)) nanoparticles fabricated by Christopher Hoimes, in the W. Mark
Saltzman Laboratory in the Yale Department of Bioengineering were encapsulated with
Nile Red, a red fluorescent dye. It has been shown that, PLGA is stable up to
temperatures of greater than 300°C; therefore, it would remain effective at temperatures
less than 50°C [120]. Functionalized nanoparticles loaded with Nile Red were suspended
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in sterile PBS and added to the individual wells at either 250µg NP/well or 1mg NP/well.
The study had two controls, human ureter fixed immediately following its removal, and
sterile PBS added to individual wells in the dot-blot. The dot-blot chambers were
incubated in humidified incubators at either 37°C or 42.5°C allowing 15 minutes to
equilibrate. Following the one hour incubation, the wells were washed four times with
sterile PBS to remove non-adherent nanoparticles. The tissue was cored with a biopsy
punch, weighed, and fixed with 10% neutral buffered formalin (VWR international) for
24 hours and transported in 70% ethanol (Decon). The tissue was sectioned by Yale
pathology tissue services (Developmental Histology Lab). Then the tissue were
deparaffinized in xylene (J.T. Baker) and rehydrated in decreasing concentrations of
ethanol. A nuclear stain, DAPI 0.1mg/mL (Cell Signaling), was applied at 1:100 in PBS,
tissue was washed and a coverslip was applied using Prolong Gold (Invitrogen). Bladder
and ureter tissue naturally fluoresce green, so no additional stains were necessary.
Penetration of the nanoparticles was monitored through fluorescence microscopy (Zeiss
Observer. Z1). Images were independently analyzed by members of the Weiss lab, under
single-blinded conditions.
Organ culture model [111]
All rat studies were approved by the Institutional Animal Care and Use
Committee of Yale University (New Haven CT). Sprague-Dawley rats were anesthetized
with 90mg/kg ketamine + 10mg/kg xylazine prior to bladder removal. Bladders were
removed sterilely and immediately transferred to a culture hood. Then, the ureters and
urethra were removed and the bladder was bisected and cut into 4-5 mm squares. Four
dots of cyanoacetate glue (Indermil) were placed equidistant into a well, and the squares
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of bladder were quickly transfixed, urothelium facing upward. Fifty microliters of
trypsin-EDTA (Gibco) in HBSS were added to the bladder and incubated for 15 minutes
at room temperature. The trypsin mixture was gently removed and 100µl of 100% FBS
(Gibco) was added and quickly removed to inactivate the residual trypsin. The bladder
cancer cell line, UM-UC-3, had previously been stably transfected a PCMV DsRedExpress2 Expression vector using the XfectTM transfection agent (Clontech) resulting in
cells that constitutively express red fluorescent protein. These red fluorescent UM-UC-3
cells, UM-UC-3R, were placed (105 to 106) in 100µl of Waymouth medium (ATCC)
with 10% FBS containing antibiotic/antimycotic agents were pipetted directly onto the
bladder surface and allowed to incubate at 37° (5% CO2, 4 hrs.). Following the cell
attachment, 4 ml of complete media was carefully added to each well, allowing it to
thinly cover the bladder. Attachment and growth of cells on the bladder were monitored
using fluorescence microscopy (Zeiss Observer. Z1). The media was then changed twice
a week, and frequently monitored for evaporation.
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IV.

RESULTS

Thermo-chemotherapy
We monitored the toxic effects of hyperthermia alone (42.5°C), in bladder cancer
cells (RT4, T24, UM-UC-3, TCCSUP) for one-hour. Cell survival under conditions of
hyperthermia alone (42.5°C) was compared with exposure to normothermia alone (37°C).
The results obtained (Table 2) showed that there was no significant difference in cell
survival between the two groups in any of the cell lines tested. Since none of these values
reached statistical significance, we assumed our two populations were non-different;
therefore we could assume that every cell line exposed to temperature alone could be
corrected to 100% cell survival.
Incubation of all five chemotherapeutic agents with all four bladder cancer cell
lines resulted in a significant decrease in proliferation. We proved statistical significance
for the decrease in cell proliferation after exposure when various dosages the of
chemotherapeutic agents (mitomycin C, doxorubicin, vinblastine, methotrexate and
cisplatin) independent of temperature. Subsequently, we were able to construct a two
phase decay equation modeled to the data to approximate the LD50 for both
normothermic and hyperthermic conditions; a correlation coefficient (r2) was generated
as an approximation for “goodness of fit.”
Mitomycin C (Figure 1, Table 3)
The combination of hyperthermia and mitomycin C had a positive impact on all
four cell lines (RT4, T24, UM-UC-3, TCCSUP), as shown (Figure 1). The RT4 cell line
had a calculated normothermic LD50 of 30.1µg/mL (p<0.05, r2=0.98), while the calculated
hyperthermic LD50 was 12.7µg/mL (p<0.05, r2=0.98), which was 42% of the
normothermic condition. The T24 cell line had a calculated normothermic LD50 of
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63.7µg/mL (p<0.05, r2=0.98) while the calculated hyperthermic LD50 was 51.3µg/mL
(p<0.05, r2=0.97), which was 80.6% of the normothermic dosage. The UM-UC-3 cell line
had a calculated normothermic LD50 of 120µg/mL (p<0.05, r2=0.98), while the calculated
hyperthermic LD50 was 50.0µg/mL (p<0.05, r2=0.99), which was 41.4% of the
normothermic dosage. The TCCSSUP cell line had a calculated normothermic LD50 of
124µg/mL (p<0.05, r2=0.84), while the calculated hyperthermic LD50 was 58.4µg/mL
(p<0.05, r2=0.92), which was 47.1% of the normothermic dosage. The synergistic effects
of hyperthermia plus chemotherapy was calculated for all the cell lines treated with
Mitomycin C (Table 4); they were 44.1%, 3.6%, 13.2%, and 29.2% for RT4 (p<0.001),
T24 (p=0.20), UM-UC-3 (p=0.003), and TCCSUP (p<0.001) cell lines, respectively.
Doxorubicin (Figure 2, Table 3)
The combination of hyperthermia and doxorubicin had a positive effect on all four
cell lines (RT4, T24, UM-UC-3, TCCSUP), as shown (Figure 2). The RT4 cell line had a
calculated normothermic LD50 of 6.28µg/mL (p<0.05, r2=0.95), while the calculated
hyperthermic LD50 was 5.52µg/mL (p<0.05, r2=0.99), which was 88% of the
normothermic dosage. The T24 cell line had a calculated normothermic LD50 of
48.2µg/mL (p<0.05, r2=0.94) while the calculated hyperthermic LD50 was 8.51µg/mL
(p<0.05, r2=0.88), which was 17.7% of the normothermic dosage. The UM-UC-3 cell line
had a calculated normothermic LD50 of 214µg/mL (p<0.05, r2=0.92), while the calculated
hyperthermic LD50 was 57.3µg/mL (p<0.05, r2=0.92), which was 26.7% of the
normothermic dosage. The TCCSSUP cell line had a calculated normothermic LD50 of
8.62µg/mL (p<0.05, r2=0.93), while the calculated hyperthermic LD50 was 6.69µg/mL
(p<0.05, r2=0.98), which was 77.6% of the normothermic dosage. The synergistic effects
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of hyperthermia plus chemotherapy was calculated for all the cell lines treated with
Doxorubicin(Table 4); they were 11.6%, 66.2%, 23.2%, and 49.6% for RT4 (p=0.26),
T24 (p=0.003), UM-UC-3 (p=0.001), and TCCSUP (p=0.002) cell lines, respectively.
Vinblastine (Figure 3, Table 3)
The combination of hyperthermia and vinblastine had a positive effect on all four
cell lines (RT4, T24, UM-UC-3, TCCSUP), as shown (Figure 3). The RT4 cell line had a
calculated normothermic LD50 of 476µg/mL (p<0.05, r2=0.96), while the calculated
hyperthermic LD50 was 421µg/mL (p<0.05, r2=0.92), which was 88.4% of the
normothermic dosage. The T24 cell line had a calculated normothermic LD50 of
376µg/mL (p<0.05, r2=0.94) while the calculated hyperthermic LD50 was 176µg/mL
(p<0.05, r2=0.97), which was 46.7% of the normothermic dosage. The UM-UC-3 cell line
had a calculated normothermic LD50 of 915µg/mL (p<0.05, r2=0.84), while the calculated
hyperthermic LD50 was 403µg/mL (p<0.05, r2=0.98), which was 44% of the
normothermic dosage. The TCCSSUP cell line had a calculated normothermic LD50 of
553µg/mL (p<0.05, r2=0.94), while the calculated hyperthermic LD50 was 198µg/mL
(p<0.05, r2=0.98), which was 35.8% of the normothermic dosage. The synergistic effects
of hyperthermia plus chemotherapy was calculated for all the cell lines treated with
Doxorubicin(Table 4); they were 21.9%, 19.1%, 86.8%, and 11.4% for RT4 (p<0.001),
T24 (p=0.003), UM-UC-3 (p<0.001), and TCCSUP (p<0.001) cell lines, respectively.
Methotrexate (Figure 4, Table 3)
The combination of hyperthermia and methotrexate was performed for all four
cell lines (RT4, T24, UM-UC-3, and TCCSUP), but only the UM-UC-3 showed a
positive effect (Figure 4). The UM-UC-3 cell line had a calculated normothermic LD50
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of 309µM (p<0.05, r2=0.94), while the calculated hyperthermic LD50 was 270µM
(p<0.05, r2=0.93), which was 87.4% of the normothermic dosage. At 0-500 µM of
methotrexate, there was no effect on the RT4 cell line, independent of temperature (data
not shown). Although there was a slight decrease in cell proliferation among the T24 and
TCCSUP cells at hyperthermic conditions compared to normothermic conditions, the
LD50 was not reached for either of these cell lines (data not shown). The synergistic effect
of hyperthermia plus chemotherapy was only calculated for UM-UC-3, as this was the
only cell line to reach the LD50, 30.9% (p=0.04) (Table 4).
Cisplatin (Figure 5, Table 3)
The combination of hyperthermia and cisplatin was performed for all four cell
lines (RT4, T24, UM-UC-3, and TCCSUP), but only the UM-UC-3 showed a positive
effect (Figure 4). The UM-UC-3 cell line had a calculated normothermic LD50 of 576µM
(p<0.05, r2=0.91), while the calculated hyperthermic LD50 was 80.8µM (p<0.05,
r2=0.94), which was 14.0% of the normothermic dosage. The methotrexate concentration
used ranged between 0-1000µM; this agent had no effect on the RT4 cell line,
independent of temperature condition (data not shown). Although there was a substantial
decrease in cell proliferation among the T24 and TCCSUP cells, the LD50 was not
reached for either of these cell lines, additionally, there was no statistical difference
between the two conditions (data not shown). The synergistic effect of hyperthermia plus
chemotherapy was only calculated for UM-UC-3, as this was the only cell line to reach
the LD50, it was 14.0% (p<0.001) (Table 4).
Belinostat
The combination of hyperthermia and belinostat was performed for all four cell
lines (RT4, T24, UM-UC-3, and TCC SUP), with none of the cell lines showing
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statistical difference between hyperthermic and normothermic conditions. At 0-1mM of
belinostat there was decreased cell proliferation at the highest concentrations in the T24,
UM-UC-3, and TCCSUP cell lines, the LD50 was never reached. The RT4 cell line had
no decrease in proliferation, even at the highest concentration (data not shown).

Mouse bladder hyperthermic model
The effect of temperature alone was investigated using mouse bladders placed at
various temperatures (37°C-50°C) for various amounts of time (1 hour-24 hours)(Figure
6). All samples were paired, from the same animal, across the three temperature
conditions to minimize subject variability. The control (Figure 6-A) was fixed
immediately after its removal, while the experimental conditions, 37°C (Figure 6-B),
42.5°C (Figure 6-C), and 50°C (Figure 6-D), were exposed for one hour at these
temperatures before fixation. The control (Figure 6-A) and 37°C (Figure 6-B) both
represent normal, healthy urothelium. In both images, the three layers of the bladder are
clearly differentiated and both have a thick, well organized urothelium, Um. The
urothelium is the location of the dome cells that maintain the impermeability of the
epithelium; the cells in this layer are large, ovoid with round, uniform nuclei and evident
eosinophilic cytoplasm. The normal scalloped appearance of the urothelium is maintained
in these tissues. The lamina propria, LP, is seen in both the images as loose collagenous
material with some small blood vessels providing oxygen and nutrients to the urothelium.
The detrusor muscle, DM, is also clearly visualized in the images; the detrusor is the
smooth muscle that allows contraction of the bladder. In the images, the detrusor muscle
contains mononucleated cells. These cells can be seen as elongated and tapering, with
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homogenous eosinophilic cytoplasm. When the tissue is exposed to therapeutic levels of
hyperthermia (42.5°C) (Figure 6-C) there is increased disorganization of the urothelium
with some evidence of pyknosis of nuclei. There is apparent exudations and vacuolization
of the lamina propria, with some pyknosis visualized. The detrusor muscle is well
maintained at this temperature. At supra-therapeutic levels of hyperthermia (50°C)
(Figure 6-D), there is increased disorganization of urothelium, with apparent
karyorrhexis, karyolysis, extensive cell membrane rupture and necrosis of the umbrella
cells. At this temperature, there is increased exudation of the lamina propria with
sloughing of the urothelium from the underlying detrusor muscle. Similar to the findings
with therapeutic hyperthermia, the detrusor muscle is well maintained at hyperthermic
conditions.
Depth of penetration
Human ureter was obtained and tested with nanoparticles which contained Nile
Red dye to test for depth of penetration. The ureter was divided into two pieces and
placed in the dot blot apparatus. The luminal side of the tissue was exposed to the
fluorescent nanoparticles. These two pieces of ureter were exposed to either hyperthermic
(42.5°C) or normothermic (37°C) conditions for one hour before fixation. The slides
were stained with DAPI, a nuclear marker, and the slides were examined using
fluorescence microscopy (Figure 7). The superficial images taken from the
normothermic condition (Figure 7-A) show the Nile red particles concentrated along the
urothelium, UM, with penetration to the Lamina Propria, LP. The deep images taken
from the normothermic condition (Figure 7-B) show a slight penetration of the
nanoparticles into the lamina propria. The superficial images taken from the hyperthermic
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condition (Figure 7-C) show the nanoparticles along the urothelium with increased
penetration of the nanoparticles into the lamina propria. The deep images of the tissue
taken from the hyperthermic condition (Figure 7-D) were examined and showed a deeper
penetration of the nanoparticles through the lamina propria onto the border of the
detrusor muscle, DM. In addition to deeper penetration, the nanoparticles were present at
a higher density when compared to normothermic conditions.
Organ Culture
Rat bladders were removed from Sprague-Dawley rats and seeded with UM-UC3R cells, which were grown for one month, with frequent examinations using light and
fluorescence microscopy (Figure 8). On day 21, light microscopy of the rat bladders
(Figure 8-A) showed cell growth along the luminal side of the tissue. When the tissue
was examined using fluorescence microscopy (Figure 8-B), these cells showed red
fluorescence, indicating that these cells were the seeded UM-UC-3R cells. This same
tissue was re-examined on day 28; light microscopy (Figure 8-C) showed continued cell
growth along the luminal side of the tissue. Again this tissue was examined using
fluorescence microscopy (Figure 8-D), again showing the red fluorescence of the
transfected UM-UC-3R cell line.
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V.

DISCUSSION
Our data suggest that the effect of therapeutic hyperthermia alone does not have

deleterious effect on cell viability since there was no significant change in cell
proliferation among the four cancer cell lines tested (RT4, T24, UM-UC-3, TCCSUP).
Our studies with combination therapy using hyperthermia and different
therapeutic agents showed a variable response depending on the cell type and the type of
agent used. When we used a combination of hyperthermia and mitomycin C, we showed
synergism for all the cell lines tested with the exception of the T24 cell line. Two
previous studies have shown synergy with mitomycin C and therapeutic hyperthermia,
but it was difficult to compare with our data as there are many inconsistencies among the
two published studies [90, 91]. The authors included three cell lines (RT112, RT4, T24)
of low-grade disease and one cell line (253J) representing high-grade invasive disease.
For example, there was a three order of magnitude difference between the LD50 of
mitomycin C for all the cell lines despite being tested using similar scientific method and
cell lines.

Additionally, neither of the published studies performed any statistical

analyses, thus it was not possible to determine if the reported results were statistically
significant. As our studies use two cell lines (RT4 and T24) that overlapped with their
work, we were able to compare the two sets of results. Our data with RT4 cell line
confirm their conclusions that there was synergy in combination therapy. In our studies
the RT4 cell line showed the greatest synergy of the four cancer cell lines. Our data
conflicted with their results for the T24 cell lines since we did not see synergy with
combination therapy. Furthermore, we showed synergy between MMC and hyperthermia
with two higher grade invasive cancer cell lines. The largest MMC dose decrease
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occurred in the UM-UC-3 cell line, with a dosage difference of 59% to achieve the LD50
for the combination therapy compared to chemotherapy alone.
Our results with doxorubicin, an anthracycline antibiotic showed synergism for
three of the four cell lines tested, but did not show synergism for the RT4 cell line. One
previous study examined epirubicin, another anthracycline antibiotic, and showed
synergy among all the cell lines tested [91]. In fact, epirubicin showed the greatest levels
of synergy compared to all the drugs tested, in particular in the T24 cell lines, although
there are a number of inconsistencies in the paper. Our data showed synergy between the
T24, UM-UC-3, and TCCSUP cell lines, with the highest synergy occurring with the T24
cell line at 66.2% compared to their value of 1,823%. Unfortunately, like the MMC data,
the authors, did not include statistical analyses and thus it was not possible to compare
with our data [91]. The T24 cell line showed the largest change in doxorubicin dose at
82% to achieve the LD50 under combined therapy compared to chemotherapy alone.
Our results with vinblastine, a microtubule inhibitor showed that it is the only
drug to display a statistically significant synergism for all the cell lines tested. No
previous studies have been published examining the combination of hyperthermia with
vinblastine for bladder cancer cell lines. The UM-UC-3 cell line showed the highest
synergy of all the cell lines tested at 87%. The TCCSUP cell line showed the largest
change, 64%, in vinblastine dose to achieve the LD50 in combined therapy compared to
chemotherapy alone.
Our results with cisplatin and methotrexate only yielded positive effects on the
UM-UC-3 cells. The UM-UC-3 cells had a modest change in methotrexate dosage
required to achieve the LD50, while cisplatin had the largest dosage difference to achieve
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the LD50 when comparing combination therapy to chemotherapy alone. Both
chemotherapeutic agents have synergy with hyperthermic conditions, methotrexate more
so than cisplatin. Our study is the only one to address the effect of these two
chemotherapeutic agents, showing their specificity for one cell line, and thus it is unlikely
that these would have wide spread application under combination therapy.
The HDAC inhibitor, belinostat, did not show any statistical difference between
combination therapy and chemotherapy alone. Prior studies in the Weiss lab showed that
belinostat had an LD50 of approximately 2.5uM after 72 hours of treatment (Martin et
al., 2013 submitted). After 24 hour incubation with belinostat, proliferation decreases
were much smaller than after 72 hours. In the current study, the LD50 was not achieved
for any of the cell lines, likely due to the fact that we only exposed the cells for one hour.
The difference in result suggests that either the cells need longer than a one hour
exposure for belinostat’s effect, or that the cells should be grown for longer than 24 hours
for belinostat’s effect to be observed. Alternatively, the lack of effect may be due to the
instability of the drug at increased temperatures that may alter its chemotherapeutic
effect.
In these studies, we looked exclusively at the increased cytotoxic effects with
hyperthermia. We found that the three most efficacious drugs tested were MMC,
doxorubicin, and vinblastine. These three agents are well known to be effective inhibitors
of cell replication machinery. For example, MMC is a potent DNA crosslinker,
doxorubicin is an inhibitor of topoisomerase II and generates free radicals, and
vinblastine is a potent inhibitor of microtubule assembly, a necessary step in cellular
replication. It is unclear why cisplatin would not have the same efficacy as MMC, as they
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share a similar mechanism of DNA crosslinking, but it is possible that the cells could
have been resistant. It is unlikely that the difference lies in the size of the molecule since
cisplatin with a molecular weight of 300.5g/mol is smaller than MMC (g/mol).
Conversely, the lower effect of methotrexate may be due to its mechanism of action
where it acts as a folate analog to inhibit DNA and protein synthesis, processes that likely
take longer than 24 hours to show its complete effect.
Of the cancer cell lines tested, UM-UC-3 was the most chemo-sensitive and
overall showed the greatest synergy between hyperthermia and chemotherapy. The T24
cell line was the most chemo-resistant of the cell lines tested, although it showed the
largest synergy when tested with doxorubicin. There was no connection between
sensitivity to combination therapy and mutations in either tumor protein 53 (TP53) or the
retinoblastoma (Rb) genes.
There are many limitations to our studies. Our limited growth time after the
treatment dose may have altered our ability to notice a statistical difference in the
chemotherapeutic agents tested. In particular, the HDAC inhibitor, methotrexate and
cisplatin could have shown an effect if tested after 72 hours of growth. Additionally,
these studies were limited as they looked exclusively at the modulation of cytotoxic or
cytostatic effects of the drugs tested under combination therapy, which does not allow us
to see the effects under physiologic conditions. It is possible that the treatments would
only be available to the superficial cells of the tumor, with no penetration into the bladder
thus hindering the efficiency of any drug tested. We also could have tested for the effect
of these drugs in combination with hyperthermia on parameters including apoptosis, cell
viability, and cell replication. These could be done using markers for apoptosis such as
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caspases 3 and 7 (executioner proteases); DNA replication could be measured using
deoxyuridine incorporation; and cell viability could be measured using ATP levels. These
markers would further delineate the effect of these various drugs on cells tested.
We strived to be consistent with current therapeutic protocols, but it would be
interesting to design a model where we could have our initial induction period, then have
maintenance therapy to see if these cells become increasingly resistant or sensitive to
combination therapy. In addition to modulating the experimental design, our current
tissue culture model system does not allow us to see how the combination therapy would
affect a tumor grown three-dimensionally. We designed the organ culture model as a
possible way to test the efficacy of combination therapy; unfortunately, the model did not
prove to be a resilient model of bladder cancer. Therefore, a xenograft or orthotopic
mouse model would validate our data, in vivo. Lastly, it would be interesting to see how
the bladder cancer cell lines would react to combination hyperthermia and BCG. It is
likely that BCG would have no effect on the cell growth, as the postulated mechanism of
BCG relies mainly on the immune response induced from the treatment.
Our organ studies revealed the effects of therapeutic (43°C) and supra-therapeutic
hyperthermia (50°C) on normal animal tissue. With increasing temperature there was
increased disorganization, necrosis and apoptosis of the urothelium. Additionally, there
was increased vacuolization of the lamina propria, with evidence of urothelial sloughing
at supra-therapeutic hyperthermia. This study allowed us to identify end organ changes.
The main limitation to this study was that these tissues were removed from the animal,
thus limiting our ability to observe the vascular or immune responses to hyperthermia.
Additionally, by conducting this study ex vivo, we were unable to observe if there is
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reversibility of the reaction following the termination of hyperthermia. In the future, it is
possible to use fluorescent stains against the cellular junction proteins to identify the
exact effects of hyperthermia on the urothelium. It is possible that there are changes to
either the gap junctions, tight junctions, or adherens junctions that create the visualized
changes and allow for the increased depth of penetration of the nanoparticles.
There have been numerous published articles detailing the depth of penetration of
drugs delivered in the bladder [61], but none of these studies showed the effects of
hyperthermia on this phenomenon. Our studies revealed that hyperthermia alone
increased the depth of penetration and density at which the nanoparticles could penetrate
into the bladder. Although the use of nanoparticles represents a good model system it
does not mimic the chemotherapeutic agents in their size or charge. In studying heated
intraperitoneal chemotherapy, many investigators used platinum based chemotherapies as
they can be easily visualized using x-ray fluorescence microscopy [121]. Therefore using
cisplatin as our chemotherapeutic agent may allow for clearer penetration studies. This
study would also benefit from the use of cellular stains to determine the possible effects
of hyperthermia on the bladder urothelium.
In conclusion, combination hyperthermia and chemotherapy holds a lot of
promise for the treatment of superficial bladder cancer as an initial therapy and as a
salvage therapy. The bladder is an excellent model to study the effects of increasing
temperature on animal physiology, not only in drug delivery, but also to study the
biochemical and molecular mechanisms of hyperthermia. With the increased usage of
intravesicular thermochemotherapy there will be an increased need to understand the
mechanisms resulting in survival benefits, to best optimize this novel therapy.
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VI.

TABLES AND FIGURES

TABLE 1. RELATION OF THE ORIGIN AND SUMMARY OF THE MOLECULAR CHARACTERISTICS OF
THE BLADDER CANCER CELLS UNDER STUDY.
RT4

T24

UM-UC-3

TCCSUP

Histopathology

Papillary
Low-grade
TCC

Invasive
TCC

Invasive
High-grade
TCC

Invasivemetastatic
High-grade
TCC

TP53* mutation

Wild type

Exon 5

Exon 4

Exon 10

RB** mutation

No

No

No

No

Total RB
Immunohistochemistry

10-20%

90%

70%

Negative

*TP53 IS TUMOR PROTEIN 53 **RB IS RETINOBLASTOMA GENE
TABLE ADAPTED FROM SANCHEZ-CARBAYO ET AL., 2002 [112]

TABLE 2: INFLUENCE OF HYPERTHERMIA, ALONE, ON CELL SURVIVAL
Bladder Cancer Cell Line
RT4
T24
UM-UC-3
TCC

% Cell Survival at 42.5°C
(±SD)*
92.5%±4.3%
92.5%±3.9%
91.2%±5.0%
90.7%±3.6%

Significance
(p-value)
0.47
0.63
0.23
0.37

*CELL SURVIVAL AT 37°C WAS ASSUMED TO BE 100% FOR ALL CELL LINES. PLATE DENSITY WAS DETERMINED USING IMAGE J (NIH)
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TABLE 3: LD50 OF CHEMOTHERAPEUTIC AGENTS WITH AND WITHOUT HYPERTHERMIA
Treatment
Mitomycin C
37°C (ug/mL)
42.5°C (ug/mL)
% Δ LD50
Doxorubicin
37°C (ug/mL)
42.5°C (ug/mL)
% Δ LD50*
Vinblastine
37°C (ug/mL)
42.5°C (ug/mL)
% Δ LD50*
Methotrexate
37°C (uM)
42.5°C (uM)
% Δ LD50*
Cisplatin
37°C (uM)
42.5°C (uM)
% Δ LD50*

LD50 RT4

LD50 T24

LD50 UM-UC-3

LD50 TCC

30.1
12.7
58%

63.7
51.3
19%

120
50.0
59%

124
58.4
53%

6.28
5.52
12%

48.2
8.51
82%

214
57.3
73%

8.62
6.69
22%

476
421
12%

376
176
53%

915
403
56%

553
198
64%

309
270
12.6%
576
80.8
86.0%

*Δ LD50 IS A CALCULATION OF THE DIFFERENCE BETWEEN THE LD50 OF THE CHEMOTHERAPY WITH AND WITHOUT HYPERTHERMIA; IT
WAS CALCULATED BY THE FOLLOWING EQUATION:

. [91]

TABLE 4: SYNERGISTIC EFFECT (IN PERCENTAGE) OF ONE HOUR HYPERTHERMIA* COMBINED
WITH CHEMOTHERAPY ON THE CELL KILLING OF FOUR HUMAN BLADDER CANCER CELL LINES,
COMPARED TO CELLS TREATED FOR ONE HOUR AT NORMOTHERMIA* WITH CHEMOTHERAPY
Treatment
Mitomycin C
Doxorubicin
Vinblastine
Methotrexate
Cisplatin

%SLD50 RT4
44.1%
+
11.6%
21.9%

%SLD50 T24
+
3.6%
66.2%
19.1%

*HYPERTHERMIA=42.5° **NORMOTHERMIA=37°C +NOT SIGNIFICANT

%SLD50 UM-UC-3
13.2%
23.2%
86.8%
30.9%
14.0%

%SLD50 TCCSUP
29.2%
49.6%
11.4%

35

FIGURE 1: Effect of combined 1-hour hyperthermia with mitomycin c (red line) on the growth of four bladder
cancer cell lines compared with normothermia and mitomycin c (blue line). Dashed line denotes LD50 axis.
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FIGURE 2: Effect of combined 1-hour hyperthermia with doxorubicin (red line) on the growth of four bladder
cancer cell lines compared with normothermia and doxorubicin (blue line). Dashed line denotes LD50 axis.
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FIGURE 3: Effect of combined 1-hour hyperthermia with vinblastine (red line) on the growth of four bladder cancer
cell lines compared with normothermia and vinblastine (blue line). Dashed line denotes LD50 axis.
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FIGURE 4: Effect of combined 1-hour hyperthermia with methotrexate (red line) on the growth
of UM-UC-3 bladder cancer cell line compared with normothermia and methotrexate (blue
line). Dashed line denotes LD50 axis.

FIGURE 5: Effect of combined 1-hour hyperthermia with cisplatin (red line) on the growth of
UM-UC-3 bladder cancer cell line compared with normothermia and cisplatin (blue line).
Dashed line denotes LD50 axis.
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RED LINE). DASHED LINE DENOTES LD50 AXIS.
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Figure 6: Rat bladders exposed to varying temperatures conditions for one hour. UM is the urothelium; LP is the
lamina propria; and DM is the detrusor muscle
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FIGURE 7: Depth of penetration experiments with human ureter exposed either to normothermic or
hyperthermic conditions with Nile red nanoparticles administered on the urothelial surface for one hour. UM
is the urothelium; LP is the lamina propria; and DM is the detrusor muscle. The bladder naturally fluoresces
green; the blue fluorescence is the DAPI nuclear stain; the arrows indicate the location of the Nile red
nanoparticles.
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A. 21 Days

B. 21 Days

C. 28 Days

D. 28 Days

FIGURE 8: Rat bladder organ culture ex-vivo, Sprague-Dawley rats were removed and seeded with UM-UC-3
cell lines transfected with red fluorescent proteins. The tissue was allowed to grow in a 5% CO2 humidified
incubator at 37°C. The tissue was frequently examined using light and fluorescence microscopy.
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